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A B S T R A C T
We present the case of an HIV-negative patient clinically diagnosed with relapsing-remitting MS who achieved
signiﬁcant disease improvement on Combivir (zidovudine/lamivudine). Within months of treatment, the patient
reported complete resolution of previously unremitting fatigue and paresthesiae, with simultaneous improve-
ments in lesion burden detected by MRI. All improvements have been sustained for more than three years. This
response may be related to the action of zidovudine as a known inhibitor of EBV lytic DNA replication, sug-
gesting future directions for clinical investigation.
1. Case report
The epidemiological link between multiple sclerosis (MS) and the
Epstein-Barr virus (EBV) is well-established (Ascherio et al., 2012), but
the role of EBV in MS pathology and clinical progression remains
controversial. Classic anti-herpesviral drugs, such as acyclovir and va-
lacyclovir, have no signiﬁcant clinical beneﬁt in MS (Friedman et al.,
2005), and are similarly ineﬀective for infectious mononucleosis,
known to be caused by primary EBV infection (Andersson et al., 1986).
Here we report a case of a patient with severe MS who experienced a
dramatic improvement after treatment with Combivir (zidovudine/la-
mivudine). Zidovudine is known to eﬀectively inhibit EBV (and no
other herpesviruses) in vitro (Lin et al., 1988), but has never been tested
in a randomized clinical trial of MS.
In September 2014, a 25-year old female student presented to her
university's health services clinic complaining of progressive inability to
feel her right leg for two months. She also felt severe fatigue and
worsening bilateral leg pain aggravated by walking. On examination,
she had bilateral lower extremity numbness and extensor plantar re-
sponse on the right side.
MRI revealed multiple small brain lesions. Additional lesions were
detected in the right peripheral cord at the C4 and C6 vertebral levels,
with gadolinium enhancement at C4. The thoracic cord contained ex-
tensive lesions spanning T7-T11 as follows: T7-T8 measuring 8mm, T9-
T10 measuring 7mm, T11 superiorly measuring 1.3 cm, and T11 in-
feriorly measuring 1.2 cm.
The patient recalled a long history of relevant clinical symptoms
including: sudden change in vision in the right eye at age 13, an episode
of unilateral lower extremity weakness at 17, bilateral leg numbness at
20, and upper extremity weakness at 24 causing her to drop a pot of
boiling water leading to second-degree burns. All symptoms had lasted
at least 24 h. While the patient had sought medical care throughout this
time, she was instructed each time to wait for improvement and return
to the clinic if symptoms did not go away on their own. Since each
symptom resolved, no follow-up occurred. Medical attention was only
sought at presentation because of decline without improvement in right
leg numbness, which was atypical compared to prior numbness, which
had disappeared on its own.
Serological testing performed at presentation was negative for HIV,
HBV, HCV, HSV1/2, syphilis, Lyme, and anti-AQP4 antibody.
Subsequently, the patient also tested negative for HTLV1/2 and CMV.
No EBV testing was performed at presentation. EBV serology was later
performed on July 31, 2017, and showed the following: EBNA1 IgG of
191, VCA IgM negative and IgG> 600, EA-D IgG negative. There was
no history of infectious mononucleosis. After MRI imaging, her primary
care provider referred her to the MS clinic at Brigham and Women's
Hospital, where she was diagnosed with clinically deﬁnite relapsing-
remitting MS (RRMS). CSF was not examined because the patient met
the diagnostic criteria for RRMS based on the McDonald criteria (2010).
In October, she was started on glatiramer acetate injections. While
on glatiramer acetate, she was sleeping more than 16 h a day without
feeling rested, developed increasingly disabling pain in her arms and
legs, and could not walk more than 100 feet without needing to sit
down. On December 2, 2014, a 3-day course of corticosteroids was
initiated for suspicion of a relapse, but decline continued.
Because of this clinical decline and local skin reactions, she stopped
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treatment with glatiramer acetate in December 2014. Repeat MRI
performed on January 9, 2015 (Fig. 1) showed a new lesion in the
cervical spine at C3 (Supplemental Figure) as well as more pronounced
lesions at C4 and C6. The patient, a medical student, after reading a
case report of MS with sustained resolution of symptoms on HAART
(Maruszak et al., 2011), independently started therapy with Combivir
(zidovudine 300mg/lamivudine 150mg) twice daily. During this time,
she was under medical supervision in accordance with standard of care
and well-established guidelines for Combivir treatment.
A few days after starting Combivir, she noticed dramatic
improvement in fatigue. After two months, she had gradual improve-
ment in numbness and pain in her arms and legs. Her neurologic exam
on March 24, 2015 (11 weeks after starting Combivir) was normal.
After nine months, she had minimal numbness in her feet, only no-
ticeable after walking for long stretches. She could go jogging for the
ﬁrst time in years.
Repeat MRI was performed on September 22, 2015 (after 8.5
months of Combivir). The previously described cervical and thoracic
cord abnormalities were signiﬁcantly less distinct compared to prior
study (Fig. 1). The brain MRI abnormalities remained stable with no
Fig. 1. Axial T2-FLAIR MRI images of the brain (A1-C1, A2-C2) immediately before, 8.5 months after, and 35 months after starting Combivir. Sagittal T2-weighted MRI images of the
cervical (A3-C3) and thoracic cord (A4, B4) before and after starting Combivir. MRI of the thoracic cord at 35 months was not performed. All imaging was done without gadolinium
contrast on 12/2017 due to lack of clinical symptoms.
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change on subsequent imaging. The patient has now been on Combivir
for more than three years. During this time, she has experienced no new
symptoms, and all described improvements, including complete cessa-
tion of MS-related fatigue, have been sustained to date. Follow-up MRIs
performed on December 7, 2016 and December 6, 2017 (Fig. 1) re-
vealed no new focal lesions.
2. Discussion
Multiple cases of patients with HIV and MS who experienced in-
deﬁnite remission or resolution of MS symptoms on HAART regimens
have been reported in the literature (Maruszak et al., 2011; Skarlis
et al., 2017; Chalkley and Berger, 2014). These have raised an im-
portant question of whether or not it is HIV infection that modulates MS
or if treatment with HAART could directly impact MS. We report this
case of an HIV-negative patient on antiretroviral therapy to support the
possibility that antiretroviral drugs may directly aﬀect MS. In parti-
cular, this case supports careful examination of drugs in the class of
nucleoside/nucleotide analogues.
Addressing the question of mechanism is critical to guide future
clinical studies in MS and most importantly, to inform drug selection for
these studies. Several mechanisms have been proposed for the impact of
HAART on MS. These mechanisms include treatment of a human en-
dogenous retrovirus by inhibition of an endogenous reverse tran-
scriptase (Maruszak et al., 2011), and chemical similarity of the fumaric
acid component of tenofovir disoproxil fumarate with dimethyl fuma-
rate (Skarlis et al., 2017; Chalkley and Berger, 2014).
We propose a diﬀerent mechanism. Given the link between EBV and
MS, it is possible that nucleoside analogues could have a direct eﬀect on
EBV, a dsDNA virus, by inhibiting lytic EBV DNA replication.
Zidovudine, a component of Combivir, is known to inhibit EBV DNA
replication. However, any mechanism must account for the lack of
clinical eﬃcacy of acyclovir-class drugs in MS and infectious mono-
nucleosis. Acyclovir drug metabolism is diﬀerent from drug metabolism
of antiretroviral nucleoside analogues because acyclovir requires a viral
kinase for phosphorylation. Bypassing this requirement facilitates the
accumulation of active drug intracellularly. This unique feature of an-
tiretroviral nucleosides may be important during low-level viral re-
plication or for pre-treatment during a period of viral latency prior to
reactivation in the CNS.
To account for the other reported cases of HIV and MS with im-
provement on HAART, this theory would require the activity of other
nucleoside analogues on lytic EBV DNA replication. We suggest this
should be tested in vitro, and that the results be used to inform drug
selection for a future clinical trial. Meanwhile, it should be emphasized
that neither Combivir nor other anti-retroviral drugs have been as of yet
proven to be eﬀective treatments for MS.
Appendix A. Supporting information
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.msard.2018.02.029.
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